Berberine
Berberine hydrochloride
Written by Aaron CuhaReviewed Sep 2026
Also known as: Berberine HCl, Rhizoma coptidis alkaloid, Nature's metformin
46 randomised trials show HbA1c down 0.73 percentage points, and a head to head against metformin found comparable glucose lowering. No outcome trial, mostly small single-region trials, and a third of patients get gastrointestinal side effects.
Overview
Berberine has the largest randomised literature of anything sold as a metabolic supplement, and the nickname it earned online is not baseless: a 2008 trial randomised 36 newly diagnosed patients to berberine or metformin and found the glucose lowering similar.
Across 46 randomised trials, berberine lowered HbA1c by 0.73 percentage points, fasting glucose by 0.86 mmol/L, and improved insulin resistance and lipids as well. Those are clinically meaningful numbers for a compound bought without a prescription.
The things that need saying alongside it: nearly all of these trials are small and from one region, no trial has measured a clinical event, and in the metformin comparison 34.5% of patients had transient gastrointestinal side effects. Berberine also inhibits CYP3A4, so it has real interaction potential with prescription drugs, which is unusual for something sold beside the vitamins.
Mechanism of action
An isoquinoline alkaloid that activates AMP-activated protein kinase, which is the same node metformin acts through, largely via mild inhibition of mitochondrial complex I raising the AMP to ATP ratio. Downstream that increases glucose uptake, suppresses hepatic gluconeogenesis and reduces lipogenesis. It also upregulates LDL receptor expression by a route independent of statins, which explains the lipid effects, and alters gut microbiota composition. Oral bioavailability is very low, under 1%, so much of the effect is likely mediated in the gut and by metabolites rather than by systemic berberine.
Human evidence
The largest randomised base of any metabolic supplement on this site, with consistent direction and clinically meaningful effect sizes, and no clinical outcome data at all.
- 46 randomised trials pooled: HbA1c down 0.73 percentage points, which is in the range expected of a low-dose oral diabetes drug.
- Against metformin directly, in 36 newly diagnosed patients over three months, glucose lowering was similar.
- Insulin resistance measures improved, with HOMA-IR down 0.71 and fasting insulin down substantially.
- Lipids improved across the same pooled analysis, with triglycerides, total cholesterol and LDL all reduced and HDL raised.
- Tolerability is the main practical limit: 34.5% of patients in the metformin comparison had transient gastrointestinal effects, which is why dosing is split across meals.
- No trial has measured cardiovascular events, progression to complications, or mortality.
What this does not tell you: Most trials are small, many are from one region, and trial quality across the pooled set is mixed, which the reviewers acknowledge. Several commercial products test berberine in combination with other agents, so those results cannot be attributed to berberine. The absence of outcome data matters more here than for most supplements, because berberine is being used as a substitute for a drug class that does have outcome data. Metformin has been tested against clinical endpoints for decades; berberine has not been tested against them at all.
Reading the research record
Berberine is the strongest case on this site for taking supplement evidence seriously, and it is also a good illustration of why replacing a drug with a supplement is a different decision than adding one. The glucose lowering is real and well replicated. What is missing is the part that takes decades and costs a fortune: whether lowering glucose this particular way prevents the things diabetes does to people. Metformin has that evidence. Berberine does not, and no sponsor has an incentive to generate it, because nobody can own the molecule. That is the economics described across this site rather than a verdict on the compound, and here it has a concrete consequence. If you are choosing between berberine and a prescribed drug, you are choosing between a compound with biomarker evidence and one with outcome evidence, and that is a conversation for the person prescribing.
The evidence, charted
Fig. 1 · evidence composition
1of 3 citations (33%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 3 distinct years, 2008 to 2021, counted from the citation list on this page.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Human2008
Efficacy of berberine in patients with type 2 diabetes mellitus
The head to head everyone cites. 36 adults with newly diagnosed type 2 diabetes randomised to berberine or metformin 0.5 g three times daily for three months, with the hypoglycaemic effect similar between them. HbA1c fell from 9.5% to 7.5% on berberine. A second arm added berberine in 48 poorly controlled patients, with HbA1c falling from 8.1% to 7.3%. 34.5% of patients had transient gastrointestinal adverse effects.
Metabolism - Review2021
The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials
46 randomised trials. HbA1c mean difference minus 0.73 (95% CI minus 0.97 to minus 0.51), fasting glucose minus 0.86 mmol/L, two-hour postprandial glucose minus 1.26 mmol/L, HOMA-IR minus 0.71 and BMI minus 1.07. Lipids improved as well. The authors describe strong evidence for efficacy, particularly as an add-on therapy.
Oxidative Medicine and Cellular Longevity - Review2019
Metabolic effect of berberine-silymarin association: a meta-analysis of randomized, double-blind, placebo-controlled clinical trials
A separate pooled analysis of berberine combined with silymarin, included here because it illustrates the formulation problem: much of the commercial literature tests combinations, and a combination result cannot be attributed to berberine alone.
Phytotherapy Research
Frequently asked questions
Is berberine as good as metformin?
On glucose lowering, one randomised head to head in 36 newly diagnosed patients over three months found the effect similar. On whether it prevents the complications of diabetes, metformin has decades of outcome data and berberine has none. Those are different questions and the second one is the one that matters over a lifetime.
How much and when?
The trials typically use 500 mg two or three times a day with meals. Splitting the dose is not arbitrary: bioavailability is under 1% and gastrointestinal side effects are common, affecting about a third of patients in the metformin comparison.
Does it interact with anything?
Yes, and this is the most important practical fact on the page. Berberine inhibits CYP3A4, which metabolises a large share of prescription drugs. It should not be treated as inert just because it is sold as a supplement. Tell whoever prescribes your medicines that you are taking it.
What marker should I watch?
HbA1c, with fasting glucose and fasting insulin alongside it. Retest at 90 days. If the number has not moved, the compound has told you what it does for you, and the pooled average does not override your own result.